Noninvasive Biomarkers in Liver Disease
Feb. 18, 2026
11 a.m.–Noon CT
Cost
Free for all participants.
Overview
Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic-associated steatohepatitis (MASH) represent the fastest-growing causes of chronic liver disease in the United States and globally. Progression from steatosis to advanced fibrosis and cirrhosis is associated with cardiometabolic comorbidities, including type 2 diabetes, obesity, dyslipidemia, and hypertension. As guidelines evolve, noninvasive testing — particularly fibrosis scoring, imaging, and direct alcohol biomarkers such as phosphatidylethanol (PEth) — is transforming how clinicians diagnose, monitor, and manage these conditions. PEth provides highly sensitive and specific detection of alcohol use and helps distinguish MASLD, MetALD, and ALD using validated threshold concentrations.
This webinar will review the latest evidence, guideline recommendations, interpretation strategies, and testing solutions to support accurate disease classification, reduce reliance on liver biopsy, and improve confidence in differentiating metabolic from alcohol-related liver injury.
Presenters
Nikola Baumann, Ph.D.
Consultant, Clinical Core Laboratory Services
Associate Professor of Laboratory Medicine and Pathology
Mayo Clinic
Rochester, Minnesota
Paul Jannetto, Ph.D.
Consultant, Clinical Biochemistry
Professor of Laboratory Medicine and Pathology
Mayo Clinic Rochester, Minnesota
Learning objectives
Upon completion of this activity, participants should be able to:
- Discuss the growing prevalence and incidence of MASLD and MASH in the U.S. and their impact on the healthcare system.
- Summarize the risk factors and comorbid conditions associated with MASLD and MASH, and the impact of these conditions on the progression and management of liver disease.
- Recognize the role of noninvasive testing in the diagnosis and management of MASLD and MASH based on key recommendations from several U.S. guidelines.
- Differentiate metabolic and alcohol-related liver disease using objective PEth biomarker thresholds to identify MASLD, MetALD, and ALD phenotypes.
- Apply current best practices for noninvasive biomarker testing to guide work-up, diagnosis, and interdisciplinary treatment planning for patients with liver disease.
Intended audience
This webinar is appropriate for gastroenterologists, hepatologists, primary care and internal medicine physicians, providers involved in the care of liver transplant candidates and patients, laboratory directors, lab supervisors, medical laboratory scientists, and laboratory send-out coordinators/managers.
Credit
The following types of credit are offered for this event:
ASCLS P.A.C.E.®
Mayo Clinic Laboratories is approved as a provider of continuing education programs in the Clinical Laboratory Sciences by the ASCLS P.A.C.E.® program. This program has been approved for a maximum of 1.0 P.A.C.E.® contact hour.
State of Florida
Mayo Clinic Laboratories is approved as a Continuing Education Accrediting Agency for the Clinical Laboratory Sciences for the State of Florida. Florida Board of Clinical Laboratory Personnel has designated this program for General (Clinical Chemistry/UA/Toxicology) credit. This program has been approved for 1.0 contact hour.
To obtain credit
1. Register for and participate in the program.
2. Complete the evaluation that will be sent to you after the program.
3. Generate and print your certificate(s).
Level of instruction for this program is intermediate.
Faculty disclosure
Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.
Questions
Contact us: mcleducation@mayo.edu
